DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

Information source: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malignant Melanoma

Intervention: Karenitecin (Drug); Valproic Acid (Drug)

Phase: Phase 1/Phase 2

Status: Terminated

Sponsored by: H. Lee Moffitt Cancer Center and Research Institute

Official(s) and/or principal investigator(s):
Adil Daud, M.D., Principal Investigator, Affiliation: UCSF (formerly at H. Lee Moffitt Cancer Center & Research Institute)

Summary

This is a Phase I study looking at the combination of Valproic Acid (VPA) and Karenitecin to treat patients with metastatic malignant melanoma. We will find the dose-limiting toxicity (DLT) and the highest dose (maximum tolerated dose) of this combination treatment that has acceptable side effects and recommend a Phase II dose level. There will be seven escalating doses of Valproic acid and one dose escalation step of

Karenitecin. Each patient shall receive one cycle of Karenitecin alone (cycle 1 days 1 - 5)

followed by the same dose of Karenitecin given in combination with VPA (cycle 2 days 1-7). Patients will receive oral VPA in divided doses for 5 days and Karenitecin starting on the 3rd day every 3 weeks (a treatment cycle). Treatment will continue until progression of disease or an unacceptable level of toxicity. After 2 cycles of treatment there will be the first efficacy evaluation or restaging of the disease. In the absence of disease progression and if there is continued safety and tolerability, treatment may continue.

Clinical Details

Official title: Phase I/II Trial of Valproic Acid and Karenitecin for Metastatic Malignant Melanoma

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Safety profile of Valproic Acid (VPA) and Karenitecin

Maximum tolerated dose (MTD) of Valproic Acid and Karenitecin

Response rate

Time to progression (TTP)

Overall survival (OS)

Secondary outcome:

Pharmacokinetic parameters of VPA and Karenitecin

Relationship between topo I expression, location and DNA strand breakage

Patient response to this drug combination

Detailed description: Treatment cycles are every 3 weeks and there are 17 study visits in all. During Phase I subjects will receive one cycle of Karenitecin alone (cycle 1 days 1-5) and then combination therapy with VPA + Karenitecin (cycle 2 days 1-7)followed by oral VPA in divided doses for 5 days and Karenitecin starting the third day (days 3-7) every 3 weeks. After 2 cycles of treatment there will be the first efficacy evaluation or restaging of the disease. Dose escalations will continue until unacceptable dose limiting toxicity (DLT) occurs, then dose escalation will be stopped and the previous dose level will be explored. In each dose level, participants will undergo pharmacokinetic (PK) sampling to determine blood levels. The melanoma skin lesions will also be biopsied to measure the effect of the combination therapy. All patients enrolled in the Phase II will be treated with VPA and Karenitecin using the dosing schedule determined to be the MTD in Phase I. In the absence of disease progression and if there is continued safety and tolerability, treatment may continue in consecutive 3 week cycles.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: Same for Phase I & II

- Cytologically/histologically-documented metastatic (stage IV) malignant melanoma

- Age greater than or equal to 18 years old

- ECOG performance status 0-2

- Subjects must be able to give informed consent and be able to follow the guidelines

given in the study

- The subject has no major impairment of hematological function, as defined by the

following laboratory parameters: WBC > 3. 0x109/L; ANC > 1. 5 x 109/L; Hgb > 9. 0g/dL; PLT >100x109/L. Red blood cell transfusions and repeat evaluations for study entry are allowed

- All subjects of reproductive potential must use an effective method of contraception

during the study and three months following termination of treatment (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)

- Subjects with biopsiable disease are preferred but not mandatory; subjects with

biopsiable disease will be encouraged to undergo biopsy. Exclusion Criteria: Phase I:

- Subjects must not have evidence of significant active infection (e. g., pneumonia,

cellulitis, wound abscess, etc.) at time of study entry.

- Subjects must have adequate renal and normal hepatic function (creatinine < 1. 5 x

upper limit of normal (ULN), bilirubin and SGOT (AST) < 1. 5 X ULN) obtained within 4 weeks prior to registration.

- Pregnant women are excluded from the study because VPA is known to cause birth

defects. Nursing mothers are excluded from this trial as effects on newborns and excretion of either drug in milk is unknown.

- Women of childbearing age must have a negative pregnancy test and be willing to use a

highly effective method of contraception. Men who are sexually active must also be willing to use an accepted and effective method of contraception.

- Subjects with uncontrolled CNS metastasis or a history of seizures are excluded.

Subjects with stable CNS metastasis (either surgically resected, treated with the gamma knife or stable for 3 months following whole brain radiotherapy are eligible) Phase II:

- Subjects must not have evidence of significant active infection (e. g., pneumonia,

cellulitis, wound abscess, etc.) at time of study entry.

- Subjects must have adequate renal and normal hepatic function (creatinine < 1. 5 x

upper limit of normal (ULN), bilirubin and SGOT (AST) < 1. 5 X ULN) obtained within 4 weeks prior to registration.

- Pregnant women are excluded from the study because VPA is known to cause birth

defects. Nursing mothers are excluded from this trial as effects on newborns and excretion of either drug in milk is unknown.

- Women of childbearing age must have a negative pregnancy test and be willing to use a

highly effective method of contraception. Men who are sexually active must also be willing to use an accepted and effective method of contraception.

- Subjects with uncontrolled CNS metastasis or a history of seizures are excluded.

Subjects with stable CNS metastasis (either surgically resected, treated with the gamma knife or stable for 3 months following whole brain radiotherapy are eligible)

- Subjects who have been previously treated with more than 2 prior chemotherapy

regimens. Any previous immunotherapy regimens are allowed.

Locations and Contacts

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States
Additional Information

Moffiitt Cancer Center Clinical Trials Website

Starting date: March 2005
Last updated: November 21, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017